Treatment of Cystic Fibrosis and Other Rare Lung Diseases

Michael S. Schechter (Hrsg.), Arata Azuma (Hrsg.)

PDF
ca. 139,09
Amazon iTunes Thalia.de Weltbild.de Hugendubel Bücher.de ebook.de kobo Osiander Google Books Barnes&Noble bol.com Legimi yourbook.shop Kulturkaufhaus ebooks-center.de
* Affiliatelinks/Werbelinks
Hinweis: Affiliatelinks/Werbelinks
Links auf reinlesen.de sind sogenannte Affiliate-Links. Wenn du auf so einen Affiliate-Link klickst und über diesen Link einkaufst, bekommt reinlesen.de von dem betreffenden Online-Shop oder Anbieter eine Provision. Für dich verändert sich der Preis nicht.

Springer Basel img Link Publisher

Naturwissenschaften, Medizin, Informatik, Technik / Pharmazie

Beschreibung

This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions.

It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.



Weitere Titel in dieser Kategorie
Cover Pharmacist Humor
Irene Xanderena
Cover Quality Assurance
Bhupinder Kumar
Cover Precision Medicine
Ingolf Cascorbi

Kundenbewertungen

Schlagwörter

Surfactant, Lymphangioleiomyomatosis, Pulmonary alveolar proteinosis, Airway surface liquid, Panbronchiolitis, Interstitial pneumonia, Mucociliary clearance, Idiopathic Pulmonary Fibrosis, Orphan drugs